Clinical Trial Update: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three dose levels of OG-6219 twice daily versus placebo in adults with moderate to severe endometriosis-related pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• OG-6219

Snippet

Sponsor: Organon and Co | Conditions: Endometriosis | Phase 2 | Status: COMPLETED